Präeklampsie: Screening und Management

Dietmar Schlembach

doi:10.1055/s-0042-122472

Hebamme, Table of Contents

Hebamme 2017; 30(01): 27-33
DOI: 10.1055/s-0042-122472

SCHWERPUNKT

Präeklampsie

Hippokrates Verlag in Georg Thieme Verlag KG Stuttgart

Präeklampsie: Screening und Management

Dietmar Schlembach

Gynäkologe, Berlin

› Author Affiliations

Abstract

Hypertensive Schwangerschaftserkrankungen (HES) treten in ca. 6–8 % aller Schwangerschaften auf. Nach wie vor stellen sie große Herausforderungen an das geburtshilfliche Team und sind entscheidend verantwortlich für maternale und fetale bzw. neonatale Morbidität und Mortalität. Ein Präeklampsie-Risikoscreening bietet die Chance zur Früherkennung und rechtzeitigen prophylaktischen Medikation.

Full Text

References

Literatur
1 Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, O’Herlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, Knight M, Lennox C, Miller A, Parmar D, Rogers J, Springett A. Saving mothers’ lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 Suppl 1: 1-203
2 Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014; 2 (6): e323-333
3 Shih T, Peneva D, Xu X, Sutton A, Triche E, Ehrenkranz RA, Paidas M, Stevens W. The Rising Burden of Preeclampsia in the United States Impacts Both Materrnal and Child Health. Am J Perinatol 2016; 33 (4): 329-338
4 Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33 (1): 8-15
5 AWMF 015/018-S1-Leitlinie 2013 Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. ( http://www.awmf.org/uploads/tx_szleitlinien/015-018l_S1_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2014-01.pdf )
6 Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 2014; 63 (18): 1815-1822
7 Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol 2011; 23 (6): 440-447
8 Schlembach D. Pre-eclampsia – still a disease of theories. Fukushima J Med Sci 2003; 49 (2): 69-115
9 Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308 (5728): 1592-1594
10 Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51 (4): 970-975
11 Leslie K, Thilaganathan B, Papageorghiou A. Early prediction and prevention of preeclampsia. Best Pract res Clin Obstet Gynaecol 2011; 25 (3): 343-354
12 Rodriguez A, Tuuli mg, Odibo AO. First-, Second-, and Third-Trimester Screening for Preeclampsia and Intrauterine Growth Restriction. Clin Lab Med 2016; 36 (2): 331-351
13 Kane SC. Fist trimester screening for preeclampsia. Obstet Med 2016; 9 (3): 106-112
14 O’Gorman N, Nicolaides KH, Poon LC. The use of ultrasound and other markers for early detection of preeclampsia. Womens Health (Lond) 2016; 12 (2): 199-207
15 Yücel B, Gedikbasi A, Dündar O, Olgac Y, Yildirim D, Yildirim G, Polat I. The utility of first trimester uterine artery Doppler, placental volume and PAPP-A levels alone and in combination to predict preeclampsia. Pregnancy Hypertens 2016; 6 (4): 269-273
16 Khong SL, Kane SC, Brennecke SP, da Silva Costa F. First-trimester uterine artery Doppler analysis in the prediction of later pregnancy complications. Dis Markers; 2015 2015: 679730
17 Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy Childbirth 2015; 15: 191
18 Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013; 33 (1): 16-27
19 Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011; 31 (1): 66-74
20 Kuc S, Wortelboer EJ, Rijn BB van, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 2011; 66 (4): 225-239
21 Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203 (4): 383.e1-8
22 Bahado-Singh RO, Jodicke C. Uterine artery Doppler in first trimester pregnancy screening. Clin Obstet Gynecol 2010; 53 (4): 879-887
23 Simeone S, Lojo C, Garcia-Esteve L, Triunfo S, Crovetto F, Arranz A, Gratacós E, Figueras F. Psychological impact of first-trimester prevention for preeclampsia on anxiety. Prenat Diagn 2015; 35 (1): 60-64
24 Harris JM, Franck L, Green B, Michie S. The psychological impact of providing women with risk information for preeclampsia: a qualitative study. Midwifery 2014; 30 (12): 1187-1195
25 East C, Conway K, Pollock W, Frawley N, Brennecke S. Women’s experiences of preeclampsia: Australian action on preeclampsia survey of women and their confidants. J Pregnancy 2011; 2011: 375653
26 Bujold E, Roberge S, Nicolaides KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn 2014; 34 (7): 642-648
27 Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Abrashi A, Bujold E. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012; 31 (3): 141-146
28 Hofmeyr GJ, Belizán JM, Dadelszen P von. Calcium and Pre-eclampsia (CAP) Study Group. Low dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG 2014; 121 (8): 951-957
29 Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, Clement AM, Coat S, Chan WS, Said J, Rey E, Robinson S, Khurana R, Demers C, Kovacs MJ, Solymoss S, Hinshaw K, Dwyer J, Smith G, McDonald S, Newstead-Angel J, McLeod A, Khandelwal M, Silver RM, Le Gal G, Greer IA, Keely E, Rosene-Montella K, Walker M, Wells PS. TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384 (9955): 1673-1683
30 Gesund schwanger. Alles, was jetzt wichtig ist. EFCNI. ( http://www.efcni.org/fileadmin/Daten/Web/Pregnancy/14_06_12_Neuauflage_Gesund_schwanger.pdf )
31 Rana S, Powe CE, Salahuddin S, Ver-lohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125 (7): 911-919
32 Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206 (1): 58.e1-8
33 Schlembach D, Verlohren S, Klein E, Lapaire O, Ramoni A, Stepan H. für die Internationale Konsensusgruppe zum Einsatz des sFlt-1/PlGF-Quotienten in der Schwangerschaft Der sFlt-1/PlGF-Quotient in Prädiktion und Diagnostik der Präeklampsie. Frauenarzt 2015; 56 (10): 858-866